Profile data is unavailable for this security.
About the company
IGM Biosciences, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing and delivering a new class of medicines to treat patients with cancer and autoimmune and inflammatory diseases. The Company’s pipeline of clinical and preclinical assets is based on the IgM antibody, which has 10 binding sites compared to conventional IgG antibodies with only two binding sites. It is also focused on creating, developing, manufacturing, and commercializing IgM antibody agonists against oncology and immunology and inflammation targets. The Company’s development programs include Aplitabart, Imvotamab, and IGM-2644. Aplitabart is an IgM antibody targeting Death Receptor 5 (DR5) proteins, being evaluated in multiple phase I combination trials for the treatment of colorectal cancer. Imvotamab is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins. IGM-2644 is a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins.
- Revenue in USD (TTM)2.11m
- Net income in USD-236.92m
- Incorporated2012
- Employees216.00
- LocationIGM Biosciences Inc325 E Middlefield RdMOUNTAIN VIEW 94043-4003United StatesUSA
- Phone+1 (650) 965-7873
- Fax+1 (302) 655-5049
- Websitehttps://igmbio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lenz Therapeutics Inc | 0.00 | -117.37m | 475.96m | 6.00 | -- | 2.40 | -- | -- | -15.88 | -15.88 | 0.00 | 7.77 | 0.00 | -- | -- | 0.00 | -44.51 | -- | -47.51 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.35 | -- | -- | -- |
| Ocugen Inc | 7.05m | -58.50m | 476.06m | 65.00 | -- | 15.73 | -- | 67.53 | -0.2348 | -0.2348 | 0.028 | 0.1176 | 0.0952 | -- | -- | 108,461.50 | -79.01 | -83.56 | -100.56 | -97.79 | -- | -- | -829.84 | -2,921.94 | -- | -- | 0.0855 | -- | 142.60 | -- | 27.33 | -- | 39.08 | -- |
| Corbus Pharmaceuticals Holdings Inc | 0.00 | -33.76m | 483.04m | 19.00 | -- | 4.90 | -- | -- | -6.97 | -6.97 | 0.00 | 9.23 | 0.00 | -- | -- | 0.00 | -38.06 | -86.84 | -49.24 | -130.46 | -- | -- | -- | -769.76 | -- | -15.43 | 0.1179 | -- | -- | -- | -5.33 | -- | -- | -- |
| Applied Therapeutics Inc | -477.00k | -193.56m | 484.49m | 26.00 | -- | 7.20 | -- | -- | -1.91 | -1.91 | -0.005 | 0.589 | -0.0053 | -- | -- | -19,080.00 | -213.60 | -140.37 | -604.11 | -240.93 | -- | -- | -- | -4,476.42 | -- | -- | 0.00 | -- | -- | -- | -45.15 | -- | -- | -- |
| Kalvista Pharmaceuticals Inc | 0.00 | -108.30m | 489.81m | 118.00 | -- | 4.53 | -- | -- | -3.14 | -3.14 | 0.00 | 2.56 | 0.00 | -- | -- | 0.00 | -68.23 | -33.56 | -75.55 | -36.55 | -- | -- | -- | -941.88 | -- | -- | 0.00 | -- | -- | -- | -12.83 | -- | -3.47 | -- |
| Tscan Therapeutics Inc | 14.81m | -96.80m | 490.57m | 161.00 | -- | 3.62 | -- | 33.12 | -1.28 | -1.28 | 0.1784 | 2.57 | 0.0715 | -- | -- | 96,181.82 | -46.72 | -- | -52.48 | -- | -- | -- | -653.50 | -- | -- | -- | 0.1974 | -- | 55.52 | -- | -34.73 | -- | -- | -- |
| Lexeo Therapeutics Inc | 0.00 | -69.42m | 494.18m | 58.00 | -- | 2.70 | -- | -- | -2.71 | -2.71 | 0.00 | 5.56 | 0.00 | -- | -- | 0.00 | -47.71 | -- | -54.30 | -- | -- | -- | -- | -- | -- | -- | 0.0091 | -- | -100.00 | -- | -12.01 | -- | -- | -- |
| IGM Biosciences Inc | 2.11m | -236.92m | 496.39m | 216.00 | -- | 3.07 | -- | 235.81 | -4.31 | -4.31 | 0.0375 | 2.74 | 0.005 | -- | -- | 9,397.32 | -56.49 | -44.66 | -62.57 | -48.20 | -- | -- | -11,255.25 | -23,668.96 | -- | -- | 0.00 | -- | 99.25 | -- | -11.45 | -- | 73.48 | -- |
| Travere Therapeutics Inc | 155.72m | -415.73m | 503.21m | 380.00 | -- | 6.79 | -- | 3.23 | -5.32 | -2.00 | 2.04 | 0.9732 | 0.2116 | 1.57 | 7.04 | 409,800.00 | -56.49 | -36.95 | -71.19 | -44.77 | 94.34 | 95.92 | -266.96 | -165.79 | 2.75 | -- | 0.836 | -- | 32.69 | -2.43 | -13.54 | -- | 16.49 | -- |
| Larimar Therapeutics Inc | 0.00 | -45.08m | 503.40m | 42.00 | -- | 2.18 | -- | -- | -0.9666 | -0.9666 | 0.00 | 3.62 | 0.00 | -- | -- | 0.00 | -24.56 | -42.22 | -26.04 | -47.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -4.51 | -- | 8.71 | -- |
| Astria Therapeutics Inc | 0.00 | -81.63m | 505.20m | 59.00 | -- | 1.85 | -- | -- | -2.32 | -2.32 | 0.00 | 6.70 | 0.00 | -- | -- | 0.00 | -27.34 | -64.48 | -28.18 | -68.34 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -40.62 | -- | -- | -- |
| OmniAB Inc | 21.05m | -63.48m | 508.10m | 106.00 | -- | 1.68 | -- | 24.14 | -0.634 | -0.634 | 0.2103 | 2.57 | 0.055 | -- | 7.18 | 198,547.20 | -16.58 | -- | -17.48 | -- | -- | -- | -301.63 | -- | -- | -- | 0.00 | -- | -42.17 | -- | -126.65 | -- | -- | -- |
| Adaptive Biotechnologies Corp | 174.50m | -215.06m | 514.32m | 709.00 | -- | 1.87 | -- | 2.95 | -1.48 | -1.48 | 1.20 | 1.87 | 0.2472 | 4.52 | 4.78 | 246,124.10 | -30.48 | -19.69 | -34.73 | -22.06 | 57.06 | 67.18 | -123.29 | -122.27 | 4.35 | -- | 0.00 | -- | -8.11 | 25.06 | -12.52 | -- | 11.11 | -- |
| Celcuity Inc | 0.00 | -73.45m | 515.61m | 55.00 | -- | 3.80 | -- | -- | -2.79 | -2.79 | 0.00 | 4.35 | 0.00 | -- | -- | 0.00 | -41.61 | -37.32 | -44.44 | -39.16 | -- | -- | -- | -- | -- | -- | 0.2193 | -- | -- | -- | -57.99 | -- | -31.12 | -- |
Data as of May 22 2024. Currency figures normalised to IGM Biosciences Inc's reporting currency: US Dollar USD
58.78%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Baker Bros. Advisors LPas of 31 Mar 2024 | 4.09m | 12.18% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 3.75m | 11.16% |
| Invus Public Equities Advisors LLCas of 31 Mar 2024 | 3.08m | 9.18% |
| Redmile Group LLCas of 31 Mar 2024 | 3.07m | 9.16% |
| Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 1.32m | 3.93% |
| Goldman Sachs & Co. LLC (Private Banking)as of 31 Mar 2024 | 1.27m | 3.78% |
| RA Capital Management LPas of 31 Mar 2024 | 937.50k | 2.79% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 841.50k | 2.51% |
| Millennium Management LLCas of 31 Mar 2024 | 695.06k | 2.07% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 681.45k | 2.03% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
